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drug-dose combination was calculated in 2006 dollars and was
compared to prices available through the November 2006 FSS.
A savings/pill was calculated to develop a nationally representa-
tive estimate of the societal savings that could be achieved if med-
ications could be obtained for FSS prices instead of current
pricing systems. RESULTS: Substitution of the FSS price could
result in a median annual per person savings in drug expendi-
tures of $308 (interquartile range, $124 to $637) for the
Medicare population, age 65 and above. The potential national
savings among these 8 classes over one year is $10.7 billion (95%
CI $10.0 billion to $11.4 billion). Among Statin medications
alone, the annual savings could be $5.9 billion (95% CI $5.4
billion to $6.4 billion) in this age group. CONCLUSION: Sub-
stantial savings in drug expenditures, in the tens of billions of
dollars, would result if Federal Supply Schedule prices were used
by Medicare in place of these commercially available prices.
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OBJECTIVES: The objective of this study was to estimate per
patient per month (PPPM) costs of medications in the six
Medicare Part D protected classes based on ﬁndings among
Medicare and dual eligible beneﬁciaries with drug coverage prior
to enactment of the beneﬁt. METHODS: Data were from the
Thomson Medstat Marketscan Medicare and Medicaid claims
databases. The study sample was constructed by identifying
patients who were enrolled either in Medicare or dually in
Medicare and Medicaid in 2004. Costs were aggregated within
each class, including patient-paid and plan-paid amounts. These
costs provided the numerators for the PPPM calculations.
Denominators were deﬁned as the aggregated patient months for
only those individuals who ﬁlled a drug within a particular class.
Drugs covered under Part B were excluded. RESULTS: The
classes where generic formulations were available (antidepres-
sants and anticonvulsants) showed lower PPPM costs ($45.31
and $50.97, respectively). The costliest class was the antiretro-
virals ($1028.13) for dual eligible patients including those age
64 and under. Among the dual eligibles over 65, immunosup-
pressants were the costliest ($657.72). In the Medicare group,
the cost of immunosuppressants ($814.86) was substantially
higher than the other ﬁve classes. The PPPM cost over all 6
classes for Medicare was $54.75, for dual eligibles it was
$157.99, and $116.35 for all patients. CONCLUSION: PPPM
costs were not uniformly high among the protected classes. The
claims data in this study allowed a “real world” check of how
much the protected classes may impact the ﬁnances of Part D.
There are differences within the classes between the dual eligible
and Medicare patients, and also within the dual eligibles by age.
This is an important message to policy makers that a change to
the structure of the protected classes in Part D may have differ-
ential effects across and also within classes.
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OBJECTIVES: Few assessments of the Medicare Part D Pre-
scription Drug Beneﬁt have been performed. We examined the
impact of the drug beneﬁt on drug utilization and out-of-pocket
expenditures. METHODS: We used pharmacy claims data from
a large national pharmacy to compare drug utilization and out-
of-pocket expenditures of Medicare eligible seniors in 2005 to
their outcomes in 2006. We used pharmacy customers aged
60–64 during the same period as a control group to capture non-
Medicare related trends in drug utilization and costs occurring
during the study period. The sample represented approximately
5.1 million unique Medicare beneﬁciaries aged 65–90 and 1.8
million unique subjects in the control group who ﬁlled and
obtained at least one prescription in pre-beneﬁt 2005 period.
RESULTS: After adjusting for individual characteristics and
socio-economic characteristics of subjects’ zip code of residence,
preliminary analyses suggest subjects’ annual drug utilization
increased by 5.5% (95% conﬁdence interval [CI] 4.7%–6.2%)
and subjects’ annual out-of-pocket expenditures decreased by
10.6% (CI 9.6%–11.9%) in 2006 as compared to 2005, net of
non-Part D related effects. Dual eligible subjects had little to no
increase in drug utilization. However, they had similar declines
in out-of-pocket expenditures as the broader beneﬁciary popu-
lation. Sensitivity analyses demonstrated that the measured
impact was not due to trend differences among different 
age groups over the study period. CONCLUSIONS: Modest
increases in prescription drug utilization and decreases in out-of-
pocket expenditures occurred for these Medicare seniors fol-
lowing the implementation of the Medicare Part D Prescription
Beneﬁt. Further work is needed to examine these patterns among
other beneﬁciaries and to evaluate the impact of these changes
on health outcomes.
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OBJECTIVES: To measure costs from complying with Medicaid
preferred drug lists (PDLs) for primary care physicians and 
cardiologists. To quantify the potential costs of a hypothetical
universal PDL for Medicare Part D as of January 2006.
METHODS: During December 2005 and January 2006 we sur-
veyed cardiologists and primary care physicians in 9 states about
their experiences with Medicaid PDLs that covered outpatient
prescriptions for statins and antihypertensives. We calculated the
opportunity cost of time spent by physicians and their staff on
requesting prior authorizations (PAs), appealing rejected PAs,
discussing PDLs with others, tracking changes to PDLs, and
receiving PDL-related training, as well as physicians’ altruistic
costs from suboptimal prescribing decisions. We used compre-
hensive prescription data from Wolters Kluwer Health (WKH)
to generate each physician’s annual prescription volume for
statins and antihypertensives separately by PDL coverage status.
We combined the survey data on PDL-related costs per physi-
cian with the WKH prescription volume data using a bootstrap
simulation to calculate total costs and the average cost per physi-
cian. We calculated the potential costs of a hypothetical univer-
sal Medicare Part D PDL by approximating the number of new
Part D prescriptions affected by PDLs and multiplying by the
survey-based average variable cost per prescription. RESULTS:
There were 986 survey respondents and 47,843 physicians with
WKH data. For statins and hypertensives, PDL cost per pre-
scription averaged $8.02 (95% CI: $7.25–$8.78)—$14.41 (95%
CI: $13.29–$15.53) off-PDL and $6.59 (95% CI: $5.91–$7.28)
on-PDL—leading to average Medicaid PDL costs per physician
of $1110 (95% CI: $1061–$1161) annually. Similar restrictions
for Medicare Part D across all therapeutic classes could have cost
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physicians $3.2 billion (95% CI: $2.88–$3.49 billion) in 2006.
CONCLUSION: Medicaid PDLs for statins and antihyperten-
sives have generated considerable costs for physicians. Physicians
would incur substantial additional costs if Medicare adopted
similarly-structured PDLs for Part D.
PODIUM SESSION I: WOMEN’S HEALTH
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OBJECTIVES: To determine the predictors of breast cancer
patients’ (BCPs) willingness to accept local and systemic therapy.
METHODS: Cross-sectional survey of BCPs ages 36–80 at the
University of Maryland Greenebaum Cancer Center, Baltimore,
MD. Since “treatment” is considered a “short-term” health state,
the chained procedure for the time trade-off (TTO) was used to
assess TTO. Willingness to accept therapy was determined using
“minimum cancer-free years to accept therapy” (CFYs) as the
dependent variable. The number of CFYs was calculated based
upon BCPs TTO responses for mastectomy (MRM), breast-con-
serving therapy (BCT), chemotherapy (CTX) and tamoxifen
(TAM). Demographic and clinical data were abstracted from
medical records. Tobit regression models were used for multi-
variate analyses. RESULTS: Mean age = 56.0 years (SD ± 9.43,
n = 77); 58.2% were white; 75.6% had early stage cancer. BCPs
required more CFYs (median = 4) to accept MRM than to accept
BCT, CTX, or TAM (median 1 year for each). For all forms of
therapy, the mode = 0, suggesting that BCPs were willing to
accept therapy even if it provided no additional CFYs. Late stage
patients required more CFYs to accept TAM (β = 6.61, p =
0.0489); similarly late stage patients in good physical health
required more CFYs to have MRM (β = 0.50, p = 0.0322). Treat-
ment-experienced BCPs were more willing to accept that type of
therapy than those who were treatment-naïve. Younger patients
(<65) required fewer CFYs to accept chemotherapy (age group
50–54, β = −4.77, p = 0.0403; 55–59, β = −7.25, p = 0.0019).
Being non-white and having less education were associated with
requiring fewer CFYs to accept to accept CTX (β = −3.86, p =
0.0087; β = −5.10, p = 0.0193, respectively). CONCLUSION:
BCPs required relatively few CFYs to accept treatment. Willing-
ness-to-accept fewer CFYs for CTX among those with less edu-
cation and of younger age is consistent with treatment patterns
previously-published. The fact that non-whites (primarily
African Americans) required fewer CFYs to accept CTX appears
in contrast to observed underutilization of CTX among African
American BCPs.
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OBJECTIVES: To assess women’s preferences/utilities for health
states speciﬁc to advanced stage breast cancer including baseline
diagnoses of advanced stage breast cancer (ABC), treatment
response, no treatment response, disease progression and espe-
cially their point of indifference between treatment-related toxi-
cities and treatment response. METHODS: FACT-B QOL data
from patients with ABC were used to compose health narratives
consisting of physical, social, emotional, functional well-being,
additional concerns content domains. Toxicities were described
separately. 100 peri/post menopausal women were interviewed
by a woman using Visual Analogue (VA) standard gamble tech-
niques (SG). Baseline ABC, treatment response, no treatment
response and disease progression were conducted using SG as
usual with oscillating risks of perfect health (1) and immediate
death (0) as anchors OR the HS narrative with 100% certainty.
For toxicity, however, the true trade-off is treatment response
with an associated risk of toxicity OR no treatment and remain-
ing with 100% certainty at baseline ABC. This allows one to
measure how much chance of response a woman needs to be
indifferent to the corresponding chance of toxicity. RESULTS:
Mean age was 55.76, 64% were postmenopausal, 11% had
breast cancer while 16% had another type of cancer previously.
VAS scores were 51.8 (p < 0.01) for baseline ABC, 82.5 (p <
0.01) for response, 57.5 (p < 0.01) for no response and 38.4 (p
< 0.01) for disease progression. SG regression results were 0.64
(p < 0.01) for baseline, 0.76 (p < 0.01) for treatment response,
0.67 (p < 0.01) for no response, and 0.50 (p < 0.01) for disease
progression. The trade-off between a chance of response with a
corresponding chance of toxicity yielded a value of 0.34 (p <
0.01) or utility score of 0.66 (p < 0.01). CONCLUSION: Women
need at least a 34% chance of treatment response to be indif-
ferent to treatment-related toxicity. These measured values are
more appropriate for Quality-adjusted Time Without Symptoms
of disease and Toxicity (Q-TWiST) analysis to value oncology
treatment.
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OBJECTIVES: To determine whether vasomotor symptom
reduction is associated with improved work productivity using
pooled data from 2 clinical trials for the relief of menopausal hot
ﬂushes with desvenlafaxine succinate (DVS). METHODS: A
total of 843 postmenopausal women experiencing 50 or more
moderate-to-severe hot ﬂushes per week received 100 or 150 mg/
day DVS or placebo in 2 randomized, double-blind, placebo-
controlled trials. Subjects kept daily hot ﬂush and sleep diaries
and completed the Proﬁle of Mood States (POMS) and Work
Limitations Questionnaire (WLQ) at baseline and week 12. To
control for multiplicity, the data were analyzed using multivari-
ate analysis of covariance (MANCOVA), adjusting for age, race,
type of menopause, and baseline values. RESULTS: At both 100-
and 150-mg doses, DVS reduced the number and severity of hot
ﬂushes from baseline to week 12 compared with placebo (all
comparisons, P < 0.0001). DVS reduced the number of night-
time awakenings due to hot ﬂushes (P < 0.0001) and improved
self-perceived sleep quality (P < 0.05) at both doses compared
with placebo. The 100 mg dose also signiﬁcantly increased the
daily number of minutes slept (P < 0.05). POMS total mood dis-
turbance score improved signiﬁcantly in both DVS dose groups
compared with placebo (P < 0.001). Work limitation, measured
by WLQ total index score, decreased signiﬁcantly from baseline
to week 12 in subjects treated with 100 mg DVS (adjusted mean
[SE] reduction = −3.3 [0.9]; P = 0.0115) compared with placebo
(−1.4 [0.9]). The 100 -mg dose group had signiﬁcant improve-
ment on the time management (P = 0.0354), mental-interper-
